Companion animal include dog, cat, fish, bird, horse, rabbit, hamster, guinea pig, and ferret. According to the National Pet Owners Survey in 2017, conducted by American Pet Products Association (APPA), around 68% of the household owns a companion animal or pet in U.S. Companion animal drug include veterinary and over-the-counter drugs, supplements, nutraceuticals, vaccines, antibiotics and parasiticides, which are used in the treatment of disease associated with digestive system, immunological system, reproductive system, respiratory, and urinary system. Increasing expenditure on animal healthcare, increasing pet ownership, increasing incidence and prevalence of zoonotic disease, are major driver attributing to the growth of market during the forecasted period.
Key features of the study:
- This report provides in-depth analysis of the North America Companion Animal Drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the North America Companion Animal Drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Zoetis Inc., Merck & Co., Inc., Bayer AG, Eli Lily & Co., Sanofi (Merial), Ceva Sante Animal, Virbac Animal Health, and Boehringer Ingelheim GmbH.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The North America Companion Animal Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America Companion Animal Drugs market
Detailed Segmentation:
- North America Companion Animal Drugs Market, By Product Type:
- Antibiotics
- Anti-inflammatory
- Parasiticides
- Ecto-Parasiticides
- Endo-Parasiticides
- Heart worm Products
- Behavioral Products
- Nutritional Products
- Skin care Products
- Vaccines
- North America Companion Animal Drugs Market, By Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
- North America Companion Animal Drugs Market, By Region:
- U.S.
- By Product Type:
- Antibiotics
- Anti-inflammatory
- Parasiticides
- Ecto-Parasiticides
- Endo-Parasiticides
- Heart worm Products
- Behavioral Products
- Nutritional Products
- Skin care Products
- Vaccines
- By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
- Canada
- By Product Type:
- Antibiotics
- Anti-inflammatory
- Parasiticides
- Ecto-Parasiticides
- Endo-Parasiticides
- Heart worm Products
- Behavioral Products
- Nutritional Products
- Skin care Products
- Vaccines
- By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
- Company Profiles
- Zoetis Inc. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co., Inc.
- Bayer AG
- Eli Lily & Co.
- Sanofi
- Ceva Sante Animal
- Virbac Animal Health
- Boehringer Ingelheim GmbH
- "*" marked represents similar segmentation in other categories in the respective section.